Researchers report innovative grass pollen allergy vaccine

Biomay, a global leader in allergy immunotherapy, announced today that the results of a landmark phase IIb study with its 3rd generation grass pollen allergy vaccine BM32 will be reported at the EAACI Congress 2015 in Barcelona, Spain. This event is a major global scientific conference in the field of allergy and clinical immunology organized by the European Academy of Allergy and Clinical Immunology. The presentation titled "Clinical efficacy of a recombinant B cell epitope-based grass pollen allergy vaccine – a phase IIb proof of concept study" will be given by Prof. Rudolf Valenta, a globally recognized leader in allergy research, on June 7, 2015, in the Hot Topic Session of the congress.

The study, which was completed in 2014, provided convincing clinical proof of concept for this first-of-kind B-cell epitope derived vaccine. It was observed that the Rhinoconjunctivitis Symptom Score (RSS) year was reduced by 25% compared to the placebo (p=0.042, statistically significant) in this 181-patient trial during the peak season in the second treatment. The treatment also significantly improved patients' well-being measured by two independent methods (Visual Analogue Scale (VAS, p=0.014) and the Rhinoconjunctivitis Quality of Life Questionnaire (RQLQ), p<0.005). A 22% difference of a Combined Symptom and Medication Score (SMS) to placebo was also found (p=0.085). The observed clinical effects were supported by a potent and sustained induction of allergen specific IgG antibodies, which are responsible for blocking the interaction of allergens with IgE on effector cells. Unlike the established allergy vaccines derived from grass pollen extracts, BM32 did not lead to any boost of disease causing IgE production, on the contrary the seasonal boost of IgE induced by pollen exposure was significantly dampened.

The treatment was safe and very well tolerated. Most side-effects were mild to moderate and resolved within a short period after drug application.

Rainer Henning, CEO of Biomay commented: "It is a great honor for Biomay that our study has been selected by the organizers for presentation in one of the most looked-for sessions of this prestigious conference. It is in recognition of the cutting edge clinical science, which has been the result of excellent cooperation between the study investigators and the company. We look forward to discussing the data with opinion leaders in the field of allergy immunotherapy from around the globe at this event."

A manuscript for submission to a leading peer reviewed journal in the field of allergy and immunology is also currently in preparation and will be submitted in due course.

Provided by PR&D, Austria
Citation: Researchers report innovative grass pollen allergy vaccine (2015, June 2) retrieved 24 April 2024 from https://medicalxpress.com/news/2015-06-grass-pollen-allergy-vaccine.html
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.

Explore further

Merck: FDA reviewing tablet to eliminate allergy

13 shares

Feedback to editors